Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865410 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions
A Phase 1 study of Healthy, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00865410: Completed Phase 1 study of Healthy, sponsored by Actavis.
NCT00865410 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 26 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865410, a Phase 1 study of Healthy, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the rate and extent of absorption of Bupropion HCl extended-release tablet (test) to that of Wellbutrin SR extended-release tablet (reference) after a single, one-tablet (150 mg) dose in fasted subjects.
Conditions Studied
Interventions
- DRUG Abrika Bupropion 150 mg Extended-Released Tablet
- DRUG Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Study Locations (1)
Florida
- SFBC Ft. Myers, Inc. - Fort Myers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
What the finished NCT00865410 record still lists
NCT00865410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Abrika Bupropion 150 mg Extended-Released Tablet is the first listed.
NCT00865410 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00865410 about?
NCT00865410 is a clinical study titled "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the rate and extent of absorption of Bupropion HCl extended-release tablet (test) to that of Wellbutrin SR extended-release tablet (reference) after a single, one-tablet (150 mg) dose in fasted subjects.
What is the current status of trial NCT00865410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2004-08. Estimated completion is 2004-09.
What conditions does trial NCT00865410 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00865410?
The interventions under investigation include: Abrika Bupropion 150 mg Extended-Released Tablet (DRUG), Wellbutrin SR® 150 mg Extended-Release Tablet, single dose (DRUG).
Who is sponsoring clinical trial NCT00865410?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00865410 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00865410's enrollment target sits among peer trials
26 760th of 1090 higher than 314 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia